![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Comparing the incidence and identifying risk factors for nephrolithiasis among patients exposed to atazanavir, other PIs and PI-free regimens
|
|
|
Reported by Jules Levin
July 20-25, AIDS 2014 - Melbourne, Australia
Ella Nkhoma, PhD1, Monica Kumar, MD2, Patricia Hines, BA3, Vidya Moorthy, MS4 1Global Pharmacovigilance and Epidemiology (GPVE), Bristol-Myers Squibb (BMS), Wallingford, CT, USA; 2GPVE, BMS, Hopewell, NJ, USA; 3Center for Observational Research and Data Sciences, BMS, Hopewell, NJ, USA; 4Mu Sigma, Northbrook, Illinois, Chicago, USA
![IAC1.gif](../images/072514/072514-5/IAC1.gif)
![IAC2.gif](../images/072514/072514-5/IAC2.gif)
![IAC3.gif](../images/072514/072514-5/IAC3.gif)
![IAC4.gif](../images/072514/072514-5/IAC4.gif)
![IAC5.gif](../images/072514/072514-5/IAC5.gif)
![IAC6.gif](../images/072514/072514-5/IAC6.gif)
![IAC7.gif](../images/072514/072514-5/IAC7.gif)
![IAC8.gif](../images/072514/072514-5/IAC8.gif)
![IAC9.gif](../images/072514/072514-5/IAC9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|